Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Talimogene laherparepvec: First in class oncolytic virotherapy

Open access
Conry, Robert M., Westbrook, Brian, McKee, Svetlana, Norwood, Timothy Graham · 2018 · Human Vaccines & Immunotherapeutics

Abstract

Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherparepvec (TVEC) is a type I herpes simplex virus genetically modified to preferentially replicate in tumor cells, enhance antigen loading of MHC class I molecules and express granulocyte-macrophage colony-stimulating factor to increase tumor-antigen presentation by dendritic cells. It is presently the only oncolytic virus approved by the FDA with an indication for advanced melanoma based upon improved durable response rate in a randomized, phase III trial. Clinical trials are underway in melanoma investigating TVEC as neoadjuvant monotherapy and in combination with checkpoint inhibitors for unresectable disease as well as in an array of other malignancies. It is appropriate to review TVEC's biology mechanism of action, clinical indication and future directions as a prototype of the burgeoning class of oncolytic viruses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21645515.2017.1412896

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 8

  1. Coffin RS, 1996, Gene Ther, 3, 886
  2. Kaufman HL, 2016, J Immuno Therapy Cancer, 6, 46
  3. Kaufman H, 2015, ASCO
  4. Robert C, J Clin Oncol, 2017
  5. Long G, J Clin Oncol, 2017
  6. Leung ACF, J Clin Oncol, 2017
  7. Robert C, 2017, Am J Health Syst Pharm, 73, 193
  8. Chang KJ, 2012, J Clin Oncol, 30

Cited by

See all 368

Metadata

Authors
Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G.
Affiliations
University of Alabama at Birmingham (US)
Corresponding author
Conry, Robert M.
Venue
Human Vaccines & Immunotherapeutics
Published
2018-02-22
Volume
14
Issue
4
Pages
839-846
ISSN
  • 2164-5515 (ISSN-L)
  • 2164-554X
OpenAlex
W2793196876
Cited by
335
References
49
Citations by year
2026: 17 · 2025: 32 · 2024: 31 · 2023: 30 · 2022: 53 · 2021: 70 · 2020: 63 · 2019: 34 · 2018: 4
FWCI
5.89
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Human Vaccines & Immunotherapeutics (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
Keywords
talimogene laherparepvec, oncolytic virotherapy, herpes simplex virus type 1, advanced melanoma, MHC class I antigen presentation, dendritic cells, GM-CSF, tumor immunology, neoadjuvant therapy, immune checkpoint inhibitors, combination therapy
MeSH terms
Animals, Antigens, Neoplasm, Dendritic Cells, Humans, Immunotherapy, Randomized Controlled Trials as Topic, Herpesvirus 1, Human, Oncolytic Virotherapy, Oncolytic Viruses

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Talimogene laherparepvec: First in class oncolytic virotherapy. https://app.cochat.ai/papers/10.1080/21645515.2017.1412896
The paper
Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018). Talimogene laherparepvec: First in class oncolytic virotherapy. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2017.1412896

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.